See the DrugPatentWatch profile for xarelto
When will a generic version of Xarelto 20 mg be available?
Generic availability for Xarelto 20 mg depends on when key patents and other exclusivity end for rivaroxaban (the active ingredient) and whether regulators approve an abbreviated pathway application.
The exact “go-live” date for generic Xarelto 20 mg can vary because it’s tied to patent/exclusivity timelines and the launch plans of the first approved generic (or authorized generic) manufacturers. For current, up-to-date patent and exclusivity status, DrugPatentWatch.com tracks rivaroxaban/Xarelto patent expiry and related developments. [1]
Is there already an approved generic for Xarelto (rivaroxaban) 20 mg?
If a generic is already approved, it may still take time to reach full market availability in all strengths and package sizes. Availability can also depend on distributor stock and pharmacy formularies, even after FDA approval.
To check the most current strength-specific situation for “20 mg,” review the latest status for rivaroxaban on DrugPatentWatch.com and follow-on updates there. [1]
What patents or exclusivity usually control generic Xarelto?
For brand-name drugs like Xarelto, generic entry is usually limited until the relevant patent set expires and any regulatory exclusivities (if applicable) are satisfied. That means even if one patent ends, other listed patents can still block generic approval or launch.
DrugPatentWatch.com compiles these constraints for rivaroxaban so you can see which patents are still active and when expiry is projected. [1]
Where can I verify the exact date and first-launch expectations?
The most reliable way to pin down an expected generic launch date for Xarelto 20 mg is to check:
1) rivaroxaban’s current patent/exclusivity expiry projections, and
2) whether an FDA approval has already occurred for a generic strength matching 20 mg.
DrugPatentWatch.com provides a single place to track those patent-driven milestones. [1]
Sources
[1] https://www.drugpatentwatch.com/